Clinical Trial Update: Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients [NA]

View source ↗

Summary

The open-label safety study of DCI-1020 in pediatric cystic fibrosis patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• DCI-1020

Snippet

Sponsor: Digestive Care, Inc. | Conditions: Digestive System Diseases, Pancreatic Disease | NA | Status: WITHDRAWN